Kenvue Inc. (BMV:KVUE)
Mexico · Delayed Price · Currency is MXN | Market Cap | 617.44B -16.7% |
| Revenue (ttm) | 268.82B +1.8% |
| Net Income | 28.93B +16.9% |
| EPS | 14.83 +14.9% |
| Shares Out | n/a |
| PE Ratio | 21.34 |
| Forward PE | 15.63 |
| Dividend | 14.56 (4.49%) |
| Ex-Dividend Date | Aug 12, 2026 |
| Volume | 6 |
| Open | 324.00 |
| Previous Close | n/a |
| Day's Range | 324.00 - 324.00 |
| 52-Week Range | 259.01 - 398.32 |
| Beta | n/a |
| Analysts | n/a |
| Price Target | n/a |
| Earnings Date | Aug 6, 2026 |
About Kenvue
Kenvue Inc. operates as a consumer health company in the United States, rest of North America, Europe, the Middle East, Africa, the Asia-Pacific, and Latin America. It operates in three segments: Self Care, Skin Health and Beauty, and Essential Health. The company offers over-the-counter medicine for cough, cold and allergy, pain care, digestive health, smoking cessation, and eye care, as well as other naturally inspired and self-care products, digital diagnostics, and telemedicine; face and body care, hair, sun, and other care products; oral a... [Read more]
Financial Performance
In 2025, Kenvue's revenue was $15.12 billion, a decrease of -2.14% compared to the previous year's $15.46 billion. Earnings were $1.47 billion, an increase of 42.72%.
Financial numbers in USD Financial StatementsNews
Kimberly-Clark seeking EU approval for $40B Kenvue takeover, Reuters reports
Kimberly-Clark (KMB) has asked EU regulators permission for its proposed $40B takeover of Kenvue (KVUE), Reuters’ Bart Meijer reports. Kimberly-Clark announced the takeover in November 2025, and the d...
Kimberly-Clark seeks EU approval for $40 billion Kenvue deal
Kimberly-Clark has asked EU regulators permission for its proposed $40 billion takeover of Tylenol maker Kenvue, documents on the EU Commission's website showed.
Kimberly-Clark Appoints Suzana Blades as Senior Vice President and General Counsel
Accomplished legal executive and global litigator brings proven track record of enterprise risk management and strategic leadership to support Kimberly-Clark's next chapter of growth DALLAS, Aug. 13, ...
Kenvue price target lowered to $19 from $20 at UBS
UBS analyst Peter Grom lowered the firm’s price target on Kenvue (KVUE) to $19 from $20 and keeps a Neutral rating on the shares. The firm updated its model post…
Kenvue Quarterly report: Q2 2026
Kenvue has published its Q2 2026 quarterly earnings report on August 6, 2026.
Kenvue Earnings release: Q2 2026
Kenvue released its Q2 2026 earnings on August 6, 2026, summarizing the period's financial results.
Kenvue misses quarterly estimates as inflation, tariffs squeeze margins
Kenvue narrowly missed Wall Street estimates for second-quarter results on Thursday as inflation, tariffs and currency-related costs squeezed margins.
Kenvue Posts Higher Profit, Sales as Turnaround Continues
Kenvue reported higher profit and sales in the second quarter, boosted by higher prices and volumes, as the company continues working to turn around its business ahead of its acquisition by Kimberly-C...
Kenvue reports Q2 adjusted EPS 31c, consensus 32c
Reports Q2 revenue $3.96B, consensus $3.97B. “We delivered our third consecutive quarter of net and organic sales growth, with broad-based gains across every segment and region,” said Kirk Perry, Chie...
Kenvue Reports Second Quarter 2026 Results
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced financial results for the fiscal second quarter ended June 28, 2026. “We delivered our third consecutive quarter of net and orga...
Drugmakers, retailers must face 'maximum strength' claim in decongestant false ad litigation in US
A federal appeals court on Thursday revived portions of nationwide litigation in which consumers accused drugmakers such as Procter & Gamble and retailers such as CVS of selling billions of dollars o...
Kenvue raises quarterly dividend 1.2% to 21c per share
Kenvue (KVUE) announced that its Board of Directors declared a quarterly dividend of 21c per share on its common stock, which represents a 1.2% increase compared to the prior quarterly…
Kenvue Increases Quarterly Cash Dividend
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) today announced that its Board of Directors declared a quarterly dividend of $0.21 per share on its common stock, which represents a 1.2 percent...
Kenvue confirms FDA approves Tylenol with Naproxen OTC combination
Tylenol announced that the U.S. Food and Drug Administration has approved Tylenol with Naproxen, which Kenvue (KVUE) calls “the first and only over-the-counter fixed-dose combination of acetaminophen ...
US FDA approves over-the-counter Tylenol combination pill for pain relief
The U.S. Food and Drug Administration on Friday approved a nonprescription, fixed-dose pill that combines Kenvue's Tylenol with the nonsteroidal anti-inflammatory drug naproxen for up to 12 hours of...
Kenvue to Announce Second Quarter 2026 Results on August 6, 2026
SUMMIT, N.J.--(BUSINESS WIRE)--Kenvue Inc. (NYSE: KVUE) will announce its second quarter 2026 financial results before the market opens on August 6, 2026. Due to the pending transaction with Kimberly-...
Kenvue price target raised to $19 from $18 at Barclays
Barclays raised the firm’s price target on Kenvue (KVUE) to $19 from $18 and keeps an Equal Weight rating on the shares. The firm adjusted targets in the consumer staples…
Kenvue price target raised to $20 from $18 at UBS
UBS raised the firm’s price target on Kenvue (KVUE) to $20 from $18 and keeps a Neutral rating on the shares.
Appeals court revives autism suits against Kenvue’s Tylenol, Bloomberg says
A New York federal appeals court revived lawsuits that claim Kenvue (KVUE) concealed alleged risks that Tylenol could cause autism in children whose mothers took the pain medication while pregnant,…
Appeals court rules Kenvue must face Tylenol autism claims, Bloomberg says
11:23 EDT Appeals court rules Kenvue (KVUE) must face Tylenol autism claims, Bloomberg says
US appeals court revives private lawsuits linking Tylenol to autism, ADHD
A federal appeals court on Monday revived hundreds of private lawsuits against Kenvue and many pharmacies and retailers, alleging that the Tylenol painkiller causes autism and attention deficit...
Kimberly-Clark price target raised to $121 from $115 at Piper Sandler
Piper Sandler raised the firm’s price target on Kimberly-Clark (KMB) to $121 from $115 and keeps an Overweight rating on the shares. Upside from Kimberly-Clark’s Kenvue (KVUE) deal doesn’t really…
Kenvue Transcript: AGM 2026
The meeting confirmed a quorum and proceeded with the election of 12 directors, approval of executive compensation, and ratification of the auditor. All proposals passed, with final results to be filed in a Form 8-K.
Kenvue Earnings release: Q1 2026
Kenvue released its Q1 2026 earnings on May 7, 2026, summarizing the period's financial results.